[5 alpha-reductase inhibitors and prostate cancer: a statement of the Committee of Cancerology of the French Association of Urology].

Abstract

INTRODUCTION:

Two randomised trials and negative conclusion of the FDA about inhibitors of 5 alpha-reductase in prevention of prostate cancer need a revision of the indications of these drugs.

METHODS:

After description of fundamentals data, review of the literature in PubMed library was performed to analyse the indications of these drugs according to the different stages of prostate cancer.

RESULTS:

Even if PCPT and REDUCE studies showed a decrease of cancers with the use of 5 alpha-reductase (5ARI) but with side effects, there is no indication for prostate cancer prevention by these drugs. In the same way, despite the results of REEDEM study, there is no indication of these drugs in active surveillance.

CONCLUSION:

Despite the large interest of these drugs, no recommendation can be given for indications of 5ARI in prevention or treatment of prostate cancer.

• Authors: P Eschwège, N Gaschignard, G Ploussard, M Peyromaure, C Bastide, L Cormier, P Mongiat-Artus, F Rozet, G Fromont, C Hennequin, R Renard-Penna, P Beuzeboc, P Richaud, M Soulié, L Salomon, les membres du CCAFU
• Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 22 Issue 10 Pg. 555-60 (Sep 2012) ISSN: 1166-7087 [Print] France
• Vernacular Title: Inhibiteurs des 5 alpha-réductases et cancer de la prostate : une mise au point du Comité de cancérologie de l'Association française d'urologie.
• PMID: 22920332 (Publication Type: English Abstract, Journal Article, Review)
• Copyright: Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Chemical References

• 5-alpha Reductase Inhibitors

Topics

• 5-alpha Reductase Inhibitors (therapeutic use)
• Humans
• Male
• Prostatic Neoplasms (prevention & control)